SomaKit TOC: Uses, Dosage & Side Effects
A radiopharmaceutical diagnostic kit for PET imaging of somatostatin receptor-positive neuroendocrine tumors using gallium-68 edotreotide
SomaKit TOC is a radiopharmaceutical diagnostic kit containing the active substance edotreotide. Before use, it must be radiolabeled with gallium-68 chloride to form gallium (68Ga) edotreotide, which is then injected intravenously for positron emission tomography (PET) imaging. This diagnostic agent binds to somatostatin receptors (particularly subtype 2) that are overexpressed on many neuroendocrine tumor cells, making these tumors visible on PET scans. SomaKit TOC is used to help detect, localize, and stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and other somatostatin receptor-positive neoplasms in adults. It is administered exclusively in specialized nuclear medicine facilities by trained healthcare professionals.
Quick Facts: SomaKit TOC
Key Takeaways
- SomaKit TOC is a radioactive diagnostic medicine used exclusively for PET imaging to detect, localize, and stage neuroendocrine tumors (NETs) that express somatostatin receptors, particularly subtype 2 (SSTR2).
- Before use, the edotreotide powder must be radiolabeled with gallium-68 chloride from a germanium-68/gallium-68 generator; the resulting gallium (68Ga) edotreotide is administered as a single intravenous injection.
- The recommended dose for adults is 100 to 200 MBq (megabecquerel); patients should drink plenty of water and urinate frequently after the procedure to reduce radiation exposure.
- SomaKit TOC is well tolerated with no formally reported side effects from clinical trials, though a potential risk of allergic reactions and injection site burning exists.
- Somatostatin analogues (octreotide, lanreotide) and glucocorticoids may interfere with imaging results, so your doctor may ask you to temporarily stop these medications before the scan.
What Is SomaKit TOC and What Is It Used For?
SomaKit TOC contains the active substance edotreotide, a synthetic peptide that mimics the natural hormone somatostatin. Somatostatin is a hormone produced throughout the body that regulates various physiological processes, including the inhibition of hormone secretion from the pituitary gland, pancreas, and gastrointestinal tract. Edotreotide is specifically designed to bind with high affinity to somatostatin receptor subtype 2 (SSTR2), which is abundantly expressed on the surface of many neuroendocrine tumor cells.
Before SomaKit TOC can be used for imaging, the edotreotide powder must undergo a preparation process called radiolabeling. In this procedure, the powder in the vial is combined with gallium-68 chloride (68Ga-chloride), a radioactive isotope produced by a germanium-68/gallium-68 (68Ge/68Ga) generator. The resulting compound, gallium (68Ga) edotreotide, retains the receptor-binding properties of edotreotide while also emitting positrons that can be detected by a PET scanner. This radiolabeling process is performed under strict conditions by specially trained nuclear medicine personnel immediately before use, as gallium-68 has a short physical half-life of approximately 68 minutes.
After the radiolabeled compound is injected intravenously, gallium (68Ga) edotreotide circulates through the bloodstream and preferentially accumulates in tissues that express somatostatin receptors, particularly SSTR2. Neuroendocrine tumors typically overexpress these receptors at much higher levels than normal tissues, which means the radiotracer concentrates in tumor sites. The positrons emitted by the gallium-68 undergo annihilation with nearby electrons, producing pairs of gamma photons that travel in opposite directions. These photon pairs are detected simultaneously by the PET scanner, allowing precise three-dimensional localization of the radiotracer and, consequently, of the tumors.
Normal physiological uptake of gallium (68Ga) edotreotide occurs in several organs that naturally express somatostatin receptors, including the pituitary gland, thyroid, spleen, adrenal glands, kidneys, pancreas, prostate, salivary glands, and various segments of the gastrointestinal tract. The liver shows moderate uptake, and excretion occurs primarily through the kidneys. Knowledge of this normal biodistribution is essential for accurate interpretation of PET images and for distinguishing physiological uptake from pathological tumor accumulation.
SomaKit TOC is indicated for the following clinical applications:
- Detection and localization of primary neuroendocrine tumors: Somatostatin receptor PET/CT with gallium (68Ga) edotreotide helps identify the primary tumor site, which is sometimes difficult to locate using conventional imaging modalities such as CT or MRI alone, particularly for small tumors in the gastrointestinal tract or pancreas.
- Staging of neuroendocrine neoplasms: The scan can reveal the full extent of disease, including metastases to lymph nodes, liver, bone, and other sites, which is critical for treatment planning and prognosis.
- Restaging and monitoring treatment response: Serial PET/CT scans can assess whether the disease has progressed, remained stable, or responded to treatment such as somatostatin analogue therapy, chemotherapy, or peptide receptor radionuclide therapy (PRRT).
- Selection of patients for PRRT: Gallium-68 somatostatin receptor imaging is used to determine whether a patient's tumors express sufficient somatostatin receptors to be eligible for targeted radionuclide therapy with agents such as lutetium-177 DOTATATE (Lutathera).
SomaKit TOC is not a treatment for neuroendocrine tumors. It is a diagnostic tool that helps doctors visualize where somatostatin receptor-positive tumors are located in your body. Your doctor has determined that the small amount of radioactivity involved in this procedure is justified by the valuable diagnostic information it provides. The clinical benefit of accurate tumor detection and staging greatly outweighs the minimal radiation risk.
What Should You Know Before Receiving SomaKit TOC?
Contraindications
There is one absolute contraindication for SomaKit TOC. You must not receive this medicine if you are allergic (hypersensitive) to edotreotide or to any of the other ingredients contained in the product. These additional ingredients include 1,10-phenanthroline, gentisic acid, mannitol, formic acid, sodium hydroxide, and water for injections. After radiolabeling, the solution also contains hydrochloric acid. If you have experienced an allergic reaction to SomaKit TOC in the past, you should not receive it again.
Warnings and Precautions
Before receiving SomaKit TOC, it is important to discuss your complete medical history with your doctor. Several conditions and circumstances can affect the safety of the procedure or the accuracy of the resulting PET images.
- Previous allergic reactions: If you have previously shown signs of an allergic reaction (such as flushing, rash, itching, nausea, or breathing difficulties) after receiving SomaKit TOC or any similar somatostatin receptor imaging agent, inform your doctor immediately. Appropriate measures will be taken to manage any reaction.
- Kidney or liver disease: Patients with impaired kidney or liver function should be monitored carefully, as these organs are involved in the excretion and metabolism of the compound. Kidney impairment may lead to slower clearance and potentially higher radiation exposure.
- Dehydration: Adequate hydration before and after the procedure is essential. Dehydration can impair kidney function and slow the elimination of radioactivity from the body, leading to increased radiation dose. You should drink plenty of water and urinate frequently.
- Recent vaccination: Vaccinations can cause lymph nodes to enlarge. These enlarged lymph nodes may take up the radiotracer and become visible on the PET scan, potentially being mistaken for tumor involvement. Inform your doctor if you have been vaccinated recently so this can be considered during image interpretation.
- Other medical conditions: Certain diseases can express somatostatin receptors and may be visible on gallium (68Ga) edotreotide PET images, potentially complicating interpretation. These include Cushing syndrome, inflammatory conditions, thyroid disorders, other tumor types (pituitary, lung, brain, breast, immune system, thyroid, adrenal, or other tumors), and conditions affecting the spleen (including previous trauma or surgery involving the spleen). Your doctor may need to perform additional scans or tests to confirm findings.
- Accessory spleen or splenosis: Some people are born with an extra spleen (accessory spleen), or may have ectopic splenic tissue in the abdomen following surgery or trauma (splenosis). Gallium (68Ga) edotreotide can highlight these structures on PET imaging, and there have been reports of such findings being confused with tumors. Your doctor will consider this possibility when interpreting your scan results.
After receiving SomaKit TOC, you will emit low levels of radiation for a short period. To protect others, avoid close contact with young children and pregnant women for 12 hours after the injection. Urinate frequently and flush the toilet twice after each use to help clear the radioactive material from your body as quickly as possible.
Pregnancy and Breastfeeding
If you are pregnant, think you might be pregnant, or are planning to become pregnant, you must inform your doctor before receiving SomaKit TOC. Nuclear medicine procedures involve exposure to ionizing radiation, which carries potential risks to the developing fetus. During pregnancy, only essential examinations should be performed where the expected diagnostic benefit clearly outweighs the potential risk to both the mother and the unborn child. Your doctor will carefully assess whether the examination is necessary.
If you are breastfeeding, your doctor may choose to delay the examination until you have stopped breastfeeding. Alternatively, you may be asked to interrupt breastfeeding and discard the expressed breast milk until there is no longer any radioactivity remaining in your body. Based on the physical half-life of gallium-68, this waiting period is at least 12 hours after the injection of SomaKit TOC. Your doctor will advise you on when you can safely resume breastfeeding.
Before the procedure, you must inform your doctor if there is a possibility that you are pregnant, if you have missed a menstrual period, or if you are currently breastfeeding. If you are uncertain about any of these matters, it is crucial to consult with your doctor, who will supervise the examination.
Children and Adolescents
SomaKit TOC is not recommended for use in patients under 18 years of age, as the safety and efficacy of this product have not been established in this age group. Children and adolescents are generally more sensitive to ionizing radiation than adults, and the risk-benefit assessment may differ. If imaging of somatostatin receptor-expressing tumors is needed in pediatric patients, alternative approaches should be discussed with a specialist.
Driving and Operating Machinery
SomaKit TOC is not considered likely to affect your ability to drive or operate machinery. The procedure itself involves lying still in a PET scanner for a period, but once completed, you should be able to resume normal activities including driving, unless your doctor advises otherwise based on your individual circumstances.
Sodium Content
SomaKit TOC contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free. This is important information for patients who are on a sodium-restricted diet.
How Does SomaKit TOC Interact with Other Drugs?
Because SomaKit TOC is a diagnostic agent used as a single administration rather than a chronic medication, its potential for drug interactions is limited compared to therapeutic drugs. However, two important categories of medications can affect the quality and accuracy of the PET images obtained with gallium (68Ga) edotreotide. Understanding these interactions is important for ensuring reliable diagnostic results.
Medications That Can Affect Image Quality
| Interacting Drug | Effect on Imaging | Clinical Recommendation |
|---|---|---|
| Somatostatin analogues (octreotide, lanreotide, pasireotide) | Compete with gallium (68Ga) edotreotide for somatostatin receptor binding sites, potentially reducing tumor uptake and causing false-negative results | Your doctor may ask you to temporarily discontinue short-acting analogues (24–48 hours before) or delay long-acting depot formulations (4–6 weeks before the scan) |
| Glucocorticoids (prednisolone, dexamethasone, hydrocortisone) | May alter somatostatin receptor expression on tumor cells and inflammatory tissues, potentially affecting tracer uptake patterns | Inform your doctor about glucocorticoid use; dose adjustments or timing modifications may be considered |
| Proton pump inhibitors (omeprazole, pantoprazole) | May cause mild physiological uptake in the gastric mucosa due to increased gastrin levels, which could be misinterpreted | Generally not required to stop; inform the nuclear medicine physician |
Mechanism of Somatostatin Analogue Interference
Somatostatin analogues such as octreotide and lanreotide work therapeutically by binding to the same somatostatin receptors that gallium (68Ga) edotreotide targets for imaging. When a patient is actively taking these medications, the somatostatin receptors on the surface of neuroendocrine tumor cells may already be occupied by the therapeutic analogue. This competitive binding means that the radiolabeled edotreotide has fewer available receptors to bind to, resulting in reduced tracer uptake in the tumor and potentially diminished visibility on the PET images.
The timing of analogue discontinuation depends on the formulation being used. Short-acting subcutaneous octreotide (Sandostatin) is typically withheld for at least 24 to 48 hours before the scan. Long-acting depot formulations such as octreotide LAR (Sandostatin LAR) or lanreotide autogel (Somatuline Autogel) have prolonged pharmacological effects lasting weeks, so ideally the scan should be scheduled just before the next planned injection, when drug levels are at their lowest. However, the decision to withhold somatostatin analogue therapy must be carefully weighed against the risk of disease flare or symptom worsening, particularly in patients with functional neuroendocrine tumors that cause carcinoid syndrome.
Glucocorticoids can also modulate somatostatin receptor expression on both tumor cells and normal tissues. In some cases, corticosteroid therapy may upregulate receptor expression, while in others it may alter the inflammatory microenvironment around tumors. These effects can influence the appearance and interpretation of PET images. Your nuclear medicine physician will take your current medications into account when reading the scan.
Tell your doctor about all medications you are currently taking, have recently taken, or might take, including over-the-counter drugs and supplements. Even medications that do not directly interact with SomaKit TOC may provide important context for interpreting your PET scan results accurately.
What Is the Correct Dosage of SomaKit TOC?
SomaKit TOC is always handled, prepared, and administered by specialized healthcare professionals who are trained and certified in the safe use of radioactive materials. The entire process—from radiolabeling to injection to imaging—takes place within designated controlled areas of a nuclear medicine department. You will not need to handle, store, or dispose of this medicine yourself.
Adults
Standard Adult Dose
Radioactivity: 100 to 200 MBq (megabecquerel) of gallium (68Ga) edotreotide
Route: Single intravenous injection
Peptide amount: 40 mcg edotreotide per vial (before radiolabeling)
The supervising physician will determine the minimum amount of radioactivity necessary to obtain the required diagnostic information. This follows the ALARA (As Low As Reasonably Achievable) principle of radiation protection.
The Procedure
Understanding what to expect during a SomaKit TOC PET scan can help you prepare and feel more comfortable. The procedure follows a standardized sequence designed to maximize image quality while minimizing radiation exposure.
- Before the injection: You should drink plenty of water before arriving at the nuclear medicine department. Adequate hydration helps ensure optimal kidney function and faster clearance of the radioactive material after the scan.
- The injection: Once the radiolabeling is complete and quality control checks have been passed, the gallium (68Ga) edotreotide solution will be administered through a vein in your arm. A single injection is sufficient for the entire examination.
- Waiting period: After the injection, you will be offered something to drink and asked to urinate immediately before the scan begins. This helps clear radioactivity from the bladder and urinary tract, which can otherwise obscure nearby structures.
- PET/CT scan: The imaging is typically performed approximately 40 to 90 minutes after injection, depending on the institutional protocol. You will lie on a table that passes through the PET/CT scanner. The scan itself usually takes 20 to 30 minutes, during which you will need to remain as still as possible.
- After the scan: Following the procedure, you should continue to drink fluids and urinate frequently to help eliminate the remaining radioactivity from your body as quickly as possible.
Children and Adolescents
SomaKit TOC is not recommended for use in patients under 18 years of age. The safety and efficacy of this product have not been established in the pediatric population. If somatostatin receptor imaging is clinically necessary for a child or adolescent, the treating physician will consider alternative approaches and discuss the risks and benefits with the patient's family.
Overdose
An overdose of SomaKit TOC is extremely unlikely because you will receive a single, carefully measured dose under the direct supervision of a nuclear medicine physician. The radioactivity level is precisely calibrated using specialized equipment before administration. In the highly unlikely event that an overdose were to occur, the primary concern would be increased radiation exposure. Treatment would focus on promoting rapid elimination of the radioactive material by encouraging the patient to drink large quantities of fluids and to empty the bladder as frequently as possible, thereby accelerating renal clearance.
The effective radiation dose from a standard 150 MBq injection of gallium (68Ga) edotreotide is approximately 3.0–4.5 mSv (millisieverts). For comparison, the average annual background radiation exposure from natural sources is about 2.4 mSv. The radiation dose from a single diagnostic PET scan is considered low and well within internationally accepted limits for medical diagnostic procedures. The kidneys and urinary bladder wall receive the highest absorbed doses among organs.
What Are the Side Effects of SomaKit TOC?
Like all medicines, gallium (68Ga) edotreotide can cause side effects, although not everybody experiences them. Because SomaKit TOC is a single-dose diagnostic agent with a very short-acting radioactive component (gallium-68 has a half-life of approximately 68 minutes), the potential for adverse effects is inherently limited compared with therapeutic medications that are taken chronically. The peptide component (edotreotide) is administered in very small quantities (40 mcg), which further minimizes the risk of pharmacological side effects.
During clinical development and post-marketing surveillance, the safety profile of gallium (68Ga) edotreotide has been characterized as follows:
Frequency Not Known
Cannot be estimated from available data
- Injection site burning or discomfort at the site of intravenous administration
- Allergic (hypersensitivity) reactions – although no cases were reported in clinical trials, the potential risk exists based on the nature of the peptide. Symptoms could include flushing, skin redness, swelling, itching, nausea, and breathing difficulties
Allergic Reactions
Although no allergic reactions to gallium (68Ga) edotreotide have been formally reported in clinical trials, there is a theoretical risk of hypersensitivity given that edotreotide is a peptide compound. As with any injectable medicine, allergic reactions can range from mild (skin rash, localized swelling, itching) to severe (anaphylaxis with breathing difficulties, rapid drop in blood pressure, and cardiovascular collapse). Healthcare staff administering SomaKit TOC are trained and equipped to recognize and treat allergic reactions immediately should they occur.
If you have previously experienced any allergic reaction to SomaKit TOC, another somatostatin analogue, or any similar peptide-based diagnostic agent, it is essential to inform your doctor before the procedure. A history of general allergic tendencies or multiple drug allergies should also be disclosed.
Incidental Imaging Findings
While not a side effect in the traditional sense, it is worth noting that gallium (68Ga) edotreotide PET imaging can occasionally reveal unexpected findings. An accessory spleen (an extra spleen present from birth) or splenosis (ectopic splenic tissue resulting from previous surgery or trauma) can take up the radiotracer and appear on the PET scan. In some cases, these findings have been initially mistaken for neuroendocrine tumors. Your doctor is aware of this possibility and may order additional scans or tests if there is any uncertainty about a finding. Similarly, inflammatory conditions, recent vaccinations, and certain benign tumors can cause somatostatin receptor uptake that may require further investigation.
Radiation Exposure
As a radioactive medicine, SomaKit TOC delivers a low dose of ionizing radiation. All ionizing radiation carries a small theoretical risk of inducing cancer or hereditary effects, although the risk from a single diagnostic procedure is extremely low. According to international radiation protection guidelines (International Commission on Radiological Protection – ICRP), the estimated lifetime additional cancer risk from the radiation dose received during a single gallium-68 PET scan is in the order of 0.01–0.02%, which is negligible compared with the background lifetime cancer risk. Your doctor will have determined that the diagnostic benefit of the procedure outweighs this extremely small radiation risk.
It is important to report any suspected side effects after receiving SomaKit TOC, even if they are not listed here. Reporting side effects helps to continuously monitor the benefit-risk balance of this medicine. You can report side effects to your national medicines regulatory authority or through your healthcare provider. Your contribution to pharmacovigilance helps ensure the ongoing safety of this and other medicines for all patients.
How Should SomaKit TOC Be Stored?
SomaKit TOC is a hospital-only product that you will never need to handle or store yourself. All storage and preparation are managed by trained nuclear medicine staff in specialized facilities that comply with national regulations governing radioactive materials. The following storage information is provided for completeness and transparency.
Before radiolabeling, the SomaKit TOC kit (containing the edotreotide powder and the reaction buffer solution) must be stored in a refrigerator at 2°C to 8°C. The product must be kept in its original packaging to protect it from light. The expiry date is printed on the outer carton, and the product must not be used after this date.
After radiolabeling with gallium-68 chloride, the resulting gallium (68Ga) edotreotide solution must be used within 4 hours. During this period, the radiolabeled solution should be stored at a temperature not exceeding 25°C. This time limitation is due to both the short half-life of gallium-68 (approximately 68 minutes) and the stability of the radiolabeled compound.
SomaKit TOC should not be used if there are visible signs of product deterioration, such as discoloration or particulate matter in the solution. Any unused product or waste material must be disposed of in accordance with local regulations for radioactive waste. This means the product cannot simply be discarded with regular hospital waste; it must either be allowed to decay to safe levels before disposal or be handled through designated radioactive waste management procedures.
As with all medicines, SomaKit TOC must be kept out of the sight and reach of children. However, given that this product is used exclusively in controlled nuclear medicine environments, contact with children is not expected to occur under normal circumstances.
What Does SomaKit TOC Contain?
Active Substance
The active substance in SomaKit TOC is edotreotide. Each vial of powder contains 40 micrograms (mcg) of edotreotide. Edotreotide is a cyclic octapeptide conjugated to the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), forming the compound also known as DOTA-[Tyr3]-octreotide or DOTATOC. The DOTA chelator enables the peptide to bind gallium-68 ions, while the octreotide-like peptide portion provides high-affinity binding to somatostatin receptor subtype 2 (SSTR2). The tyrosine substitution at position 3 (Tyr3) enhances SSTR2 binding affinity compared with native octreotide.
Inactive Ingredients
The other ingredients in SomaKit TOC serve specific purposes in the radiolabeling process and product stability:
- 1,10-Phenanthroline: Acts as a metal ion scavenger to prevent interference from trace metals during the radiolabeling reaction.
- Gentisic acid: A radical scavenger that protects the radiolabeled compound from radiolytic degradation caused by the radioactive gallium-68.
- Mannitol: A sugar alcohol used as a bulking agent and stabilizer for the lyophilized (freeze-dried) powder.
- Formic acid: Used as a pH-adjusting agent in the reaction buffer to optimize conditions for the radiolabeling reaction.
- Sodium hydroxide: Used for pH adjustment.
- Water for injections: The solvent for the reaction buffer solution.
- Hydrochloric acid: Present in the final radiolabeled solution as a result of the radiolabeling process.
Kit Contents and Appearance
SomaKit TOC is supplied as a radiopharmaceutical preparation kit containing two components:
- Vial 1 (black snap cap): A glass injection vial containing a white lyophilized (freeze-dried) powder. This vial contains the edotreotide peptide along with 1,10-phenanthroline, gentisic acid, and mannitol.
- Vial 2 (yellow snap cap): A cyclic olefin polymer injection vial containing a clear, colorless reaction buffer solution (formic acid, sodium hydroxide, and water for injections).
Importantly, the radioactive component (gallium-68) is not included in the kit. The gallium-68 chloride is generated separately from a germanium-68/gallium-68 (68Ge/68Ga) generator, which is maintained in the nuclear medicine facility. The radiolabeling process, in which gallium-68 chloride is combined with the SomaKit TOC components, is performed by trained nuclear medicine professionals immediately before the product is administered to the patient.
After successful radiolabeling, the final solution should be clear, colorless, and free of visible particles. Quality control testing is performed before each patient dose is released for injection, including radiochemical purity assessment to ensure that at least 95% of the gallium-68 is properly bound to the edotreotide peptide.
Frequently Asked Questions About SomaKit TOC
A regular CT scan provides detailed anatomical (structural) images of your body using X-rays. A SomaKit TOC PET scan provides functional information by showing where somatostatin receptors are active, which helps identify neuroendocrine tumors. In practice, these two modalities are combined in a PET/CT scan, which overlays the functional PET data onto the anatomical CT images, providing both structural and molecular information simultaneously. This combination is more accurate for detecting and characterizing neuroendocrine tumors than either modality alone, as it can reveal small tumors and metastases that may be invisible on CT alone.
The total time from injection to completion of the scan is typically 1 to 2 hours. After the intravenous injection of gallium (68Ga) edotreotide, there is a waiting period of approximately 40 to 90 minutes to allow the radiotracer to distribute to somatostatin receptor-expressing tissues. During this time, you will be asked to drink fluids and urinate. The PET/CT scan itself usually takes 20 to 30 minutes, during which you lie still on the scanner table. Including preparation time and the post-scan period, you should plan to spend approximately 2 to 3 hours at the nuclear medicine department.
The only potentially uncomfortable part of the procedure is the intravenous injection, which is similar to a standard blood draw or any other injection into a vein. Some patients may feel a brief stinging or burning sensation at the injection site. The PET/CT scan itself is completely painless. You simply lie on a table that moves slowly through the scanner. The main requirement is to remain still during the scan, which some patients may find slightly uncomfortable depending on their condition, but it is not painful. If you experience anxiety about enclosed spaces, inform your healthcare team in advance.
Yes, you can generally resume your normal daily activities immediately after the scan. There is no sedation involved, so you can drive yourself home. The main precaution is to avoid close contact with young children and pregnant women for 12 hours after the injection, as you will be emitting very low levels of radiation during this time. You should also continue to drink plenty of fluids and urinate frequently for several hours after the procedure to help flush the remaining radioactivity from your body. The gallium-68 has a very short half-life (approximately 68 minutes), so the radioactivity decays rapidly.
Your doctor may recommend a SomaKit TOC PET/CT scan because it provides unique molecular information about somatostatin receptor expression that cannot be obtained from conventional imaging methods like CT, MRI, or ultrasound alone. Somatostatin receptor PET has been shown to be significantly more sensitive and specific for detecting neuroendocrine tumors compared with CT alone, particularly for small primary tumors, lymph node metastases, and bone metastases. Additionally, the results help determine whether you may be a candidate for peptide receptor radionuclide therapy (PRRT) with agents like lutetium-177 DOTATATE, which targets the same somatostatin receptors.
There are several gallium-68 labeled somatostatin analogues used for PET imaging, including 68Ga-DOTATOC (SomaKit TOC), 68Ga-DOTATATE, and 68Ga-DOTANOC. All three target somatostatin receptors but with slightly different binding profiles. DOTATOC and DOTATATE primarily bind SSTR2, while DOTANOC has broader affinity for SSTR2, SSTR3, and SSTR5. In clinical practice, studies have shown that all three tracers provide broadly comparable diagnostic performance for neuroendocrine tumors. The choice between them is typically based on institutional availability, local expertise, and regulatory approval. DOTATATE tends to have slightly higher SSTR2 affinity, while DOTATOC has a somewhat higher tumor-to-background ratio in some settings.
References
- European Medicines Agency (EMA). SomaKit TOC – Summary of Product Characteristics (SmPC). Last updated 2025. Available at: www.ema.europa.eu
- Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(10):2004-2010.
- Hofman MS, Lau WFE, Hicks RJ. Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation. RadioGraphics. 2015;35(2):500-516.
- Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology. 2017;105(3):212-244.
- Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal of Nuclear Medicine. 2018;59(1):66-74.
- Deppen SA, Blume J, Bober AJ, et al. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine. 2016;57(6):872-878.
- International Commission on Radiological Protection (ICRP). Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. Annals of the ICRP. 2015;44(2S).
- World Health Organization (WHO). Radiation Protection in Medicine: Setting the Scene for the Next Decade. WHO Technical Report Series, No. 1000. Geneva: WHO; 2021.
Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – specialists in nuclear medicine, diagnostic imaging, and clinical pharmacology
Medical Review
Reviewed by iMedic Medical Review Board following EMA, EANM, SNMMI, and ENETS guidelines
Evidence Standard
Level 1A evidence – based on systematic reviews, meta-analyses, and international clinical guidelines
Independence
No pharmaceutical company funding, sponsorship, or advertising influences our content
Last reviewed: | Next review: | Meet our medical team